OrbiMed Raises $3 Billion for Two New Healthcare Funds, Split Between US-Europe Venture and Asia Growth

OrbiMed, the global healthcare investment firm, announced on October 15, 2026 that it has raised $3 billion in commitments across two new private equity funds: OrbiMed Private Investments X, with over $1.9 billion for U.S. and European life sciences venture capital, and OrbiMed Asia Partners VI, with over $1 billion for healthcare growth equity and venture capital across Asia. For founders, the split defines a clear decision boundary: geography and stage determine which fund is even a candidate.

OrbiMed Raises $3 Billion for New Healthcare Funds

The New York-based firm, which secondary reporting notes holds more than $21 billion in assets under management, framed the dual raise as a continuation of its global strategy. Both funds, according to OrbiMed's announcement, seek to build leading healthcare companies focused on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The two vehicles are the tenth and sixth iterations of OrbiMed's long-running private investment and Asia Partners franchises, signaling institutional continuity rather than a new strategy.

OrbiMed Private Investments X: Focus on US and Europe

The larger of the two vehicles, Private Investments X, raised over $1.9 billion and will target venture-stage life sciences businesses in the U.S. and Europe. Reporting on the announcement notes that companies developing new therapeutics, medical technologies and diagnostic products in these markets frequently require substantial capital to advance research, clinical development and commercialization — the funding gap this fund is positioned to fill. Its mandate is squarely early-stage: venture capital opportunities, not late-stage expansion.

OrbiMed Asia Partners VI: Targeting Asia's Healthcare Growth

Asia Partners VI raised over $1 billion and carries a deliberately broader stage mandate. The fund will pursue both venture capital and growth equity investments across Asian markets, allowing OrbiMed to back emerging healthcare companies as well as businesses seeking capital to expand existing operations. That dual-stage flexibility distinguishes it from its U.S.-Europe sibling and widens the aperture for Asian companies at later development points.

OrbiMed's New Funds: A Comparative Overview

The table below isolates the distinct characteristics of each fund from OrbiMed's announcement and secondary reporting, so a founder or investor can quickly assess which vehicle aligns with a company's geography, stage and sector.

The side-by-side comparison shows the funds share an identical sectoral mandate but diverge on capital size, geography and stage. A U.S. or European venture-stage company has one candidate fund; an Asian company anywhere from venture through growth has the other.

OrbiMed's Fundraising Trend: A Historical Perspective

The $3 billion raise continues a pattern of large, recurring dual-geography fund cycles. In October 2023, OrbiMed announced more than $4.3 billion across OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV, spanning seed stage through growth capital. Its 2021 cycle raised $3.5 billion across predecessor funds including Private Investments VIII and Asia Partners IV.

The predecessor funds' stated parameters illustrate the model's consistency. Private Investments VIII targeted venture-stage opportunities in North America and Europe with investments of $10 million to $100 million across roughly 40 portfolio companies, while Asia Partners IV invested primarily in China and India from venture through growth stage, at similar check sizes across approximately 20 companies. The new funds' naming, regional split and stage structure track that lineage closely, though the 2026 total is smaller than the 2023 raise — which included a royalty and credit vehicle absent from the current announcement.

Implications for Life Sciences Startups

For founders, the practical consequence is a major new pool of capital targeted at specific points on the map and the development curve. A venture-stage biopharma, device or diagnostics company in the U.S. or Europe fits the Private Investments X profile; an Asian healthcare business at either the venture or expansion stage fits Asia Partners VI. The announcement does not disclose check sizes or portfolio-company counts for the new funds, so founders cannot yet calibrate ticket expectations from the current release alone — though predecessor funds' $10 million to $100 million range offers a historical reference point, not a stated commitment.

Competing healthcare investors also face a better-capitalized incumbent in both regions. The analysis here rests solely on public announcements and does not include limited partner information or internal firm strategy, and nothing in the announcement constitutes investment advice.

Assessing Alignment with OrbiMed's New Funds

Life sciences startups should evaluate their geographic location, development stage, and therapeutic area to determine potential fit with OrbiMed Private Investments X or OrbiMed Asia Partners VI. The concrete test: a U.S. or European venture-stage company in biopharmaceuticals, medical devices, diagnostics or technology-enabled healthcare services maps to the $1.9 billion fund; an Asian company at venture or growth stage maps to the $1.1 billion fund. The measurable indicator to watch next is the announcement of initial portfolio company investments from OrbiMed Private Investments X and OrbiMed Asia Partners VI, which will show the actual check sizes, sectors and stages the firm deploys against its stated mandate.

Sources

• OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds - OrbiMed
• OrbiMed Raises $3 Billion Across U.S., European and Asian Healthcare Investment Funds — citybiz
• OrbiMed Raises $3.5 Billion Across Private Investment Funds - OrbiMed